Predictors of Stroke Outcome Extracted from Multivariate Linear Discriminant Analysis or Neural Network Analysis

Tomohisa Nezu¹, Naohisa Hosomi^{2,3}, Kazumasa Yoshimura⁴, Daisuke Kuzume², Hiroyuki Naito¹, Shiro Aoki¹, Yuko Morimoto², Masato Kinboshi², Takeshi Yoshida⁵, Yuji Shiga¹, Naoto Kinoshita¹, Akira Furui⁴, Genta Tabuchi⁴, Hiroki Ueno¹, Toshio Tsuji⁴ and Hirofumi Maruyama¹

¹Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan

²Department of Neurology, Chikamori Hospital, Kochi, Japan

³Department of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

⁴Faculty of Engineering, Hiroshima University, Higashi-Hiroshima, Japan

⁵Department of Rheumatology, Chikamori Hospital, Kochi, Japan

Aim: The prediction of functional outcome is essential in the management of acute ischemic stroke patients. We aimed to explore the various prognostic factors with multivariate linear discriminant analysis or neural network analysis and evaluate the associations between candidate factors, baseline characteristics, and outcome.

Methods: Acute ischemic stroke patients ($n=1,916$) with premorbid modified Rankin Scale (mRS) scores of 0–2 were analyzed. The prediction models with multivariate linear discriminant analysis (quantification theory type II) and neural network analysis (log-linearized Gaussian mixture network) were used to predict poor functional outcome (mRS 3–6 at 3 months) with various prognostic factors added to age, sex, and initial neurological severity at admission.

Results: Both models revealed that several nutritional statuses and serum alkaline phosphatase (ALP) levels at admission improved the predictive ability. Of the 1,484 patients without missing data, 560 patients (37.7%) had poor outcomes. The patients with poor outcomes had higher ALP levels than those without (294.3 ± 259.5 vs. 246.3 ± 92.5 U/l, $P<0.001$). Multivariable logistic analyses revealed that higher ALP levels (1-SD increase) were independently associated with poor stroke outcomes after adjusting for several confounding factors, including the neurological severity, malnutrition status, and inflammation (odds ratio 1.21, 95% confidence interval 1.02–1.49). Several nutritional indicators extracted from prediction models were also associated with poor outcome.

Conclusion: Both the multivariate linear discriminant and neural network analyses identified the same indicators, such as nutritional status and serum ALP levels. These indicators were independently associated with functional stroke outcome.

Key words: Neural network analysis, Acute ischemic stroke, Outcome

Introduction

Predicting functional outcomes after acute ischemic stroke is important because patients with physical disability at hospital discharge require varying levels of rehabilitation or long-term care after

discharge. Neurological severity at stroke onset is one of the most important factors for predicting long-term functional outcomes. Simple and reliable assessments based on age and the National Institutes of Health Stroke Scale (NIHSS) score have been widely used to predict functional outcomes among acute stroke

Address for correspondence: Tomohisa Nezu, Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, Hiroshima 734-8551, Japan E-mail: tomonezu@hiroshima-u.ac.jp

Received: August 3, 2020 Accepted for publication: October 12, 2020

Copyright©2021 Japan Atherosclerosis Society

This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.

Advance Publication Journal of Atherosclerosis and Thrombosis

Accepted for publication: October 12, 2020 Published online: December 9, 2020

patients¹⁻³). In clinical settings, blood laboratory and neurological findings are essential for acute ischemic stroke. We reported previously that malnutrition status based on laboratory findings at admission is independently associated with poor stroke outcome after adjusting for baseline characteristics, including age, sex, and the NIHSS score⁴). In that study, nutritional status was evaluated using the Controlling Nutritional Status (CONUT) score⁵), which is calculated from the serum albumin concentration, total peripheral lymphocyte count, and total cholesterol level. Conversely, several other simple scores calculated from laboratory findings, including lymphocyte count, neutrophil count, platelet count, albumin levels, and C-reactive protein levels, were proposed. These indicators are also associated with stroke outcomes⁶⁻¹⁰). Other studies have shown that hemoglobin levels, plasma D-dimer levels, and decreased estimated glomerular filtration rate are associated with stroke outcomes¹¹⁻¹⁴). Although accumulated evidence suggested that blood laboratory findings at admission are useful for predicting stroke outcomes, weighing those laboratory parameters relative to each other or evaluating their priority because of the various fluctuations in the ranges of laboratory findings are sometimes difficult. Additionally, it remains unclear which laboratory parameters at admission, besides age, sex, and the NIHSS score, improve the predictive ability for stroke outcomes.

Machine learning has recently been applied to predict clinical outcomes in several medical fields. This method may provide a promising factor or scoring system for predicting clinical outcomes unlike traditional analysis models based on the assumption of a linear relationship between selected variables and the log odds of outcomes. The log-linearized Gaussian mixture network (LLGMN), a kind of machine learning method, has been used for pattern classification problems of various bioelectric signals¹⁵⁻¹⁷). In the present study, we aimed to find useful blood laboratory parameters besides age, sex, and neurological severity (the NIHSS score) to improve the predictive ability for acute ischemic stroke outcome using both traditional and neural network analyses. Additionally, we evaluated the clinical significance of indicators extracted from those analyses to correspond to the stroke functional outcome.

Methods

Study Population

This was a double-center, hospital-based retrospective study involving patients with acute

ischemic stroke within 7 days after stroke onset hospitalized at Hiroshima University and Chikamori Hospital between October 2009 and September 2018. Patients with intravenous thrombolysis or endovascular treatment were excluded from this study. A total of 2,359 consecutive patients were enrolled. This study complies with the Declaration of Helsinki guidelines for investigations involving humans, and the study protocol was approved by the Ethics Committees of Hiroshima University and Chikamori Hospital. This study was conducted under the opt-out method, as it was conducted retrospectively using clinical records.

Assessment of Clinical Characteristics

The following clinical characteristics were recorded at admission: age, sex, body mass index (BMI), and classical vascular risk factors including hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease (CKD), atrial fibrillation, daily alcohol intake (>40 g), smoking habit (current smokers or non-current smokers), and history of stroke and ischemic heart disease. Criteria for hypertension, diabetes mellitus, dyslipidemia, and atrial fibrillation were previously defined⁴). CKD was evaluated by eGFR using the equation of the Japanese Society of Nephrology: $eGFR = 194 \times \text{creatinine (Cr)}^{-1.094} \times \text{age}^{-0.287}$ (mL/min/1.73 m²). For women, the eGFR was multiplied by a correction factor of 0.739¹⁸). CKD was defined as an eGFR level <60 mL/min per 1.73 m². Atrial fibrillation was diagnosed when a previous electrocardiography (ECG) or ECG conducted on admission revealed atrial fibrillation. Neurological severity was assessed according to the NIHSS score. Stroke subtypes were classified according to the criteria established by the Trial of ORG 10172 in Acute Stroke Treatment classification¹⁹).

Laboratory Parameters

Supplemental Table 1 lists the laboratory parameters. These parameters are basically used to manage patients with acute stroke in daily clinical settings in our hospitals. Most blood samples were collected at admission, and some findings, such as hemoglobin A1c (HbA1c) or cholesterol levels, were obtained within 2 days after admission. We calculated the following scores reflected as nutritional status or inflammation. The CONUT scores were calculated from the serum albumin concentration, total peripheral lymphocyte count, and total cholesterol concentration⁵). The Geriatric Nutritional Risk Index (GNRI) was calculated from serum albumin levels and BMI²⁰). The NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio), and CAR (CRP-

to-albumin ratio) were also calculated^(6, 21).

Assessment of Stroke Outcomes

The primary outcome was evaluated from the 3-month functional status. A poor outcome was defined as a score of 3–6 on the modified Rankin Scale (mRS); a score of 0–2 was defined as a good outcome. Secondary outcomes were an mRS score of 0–1 at 3 months and death at 3 months. Essentially, attending physicians evaluated the mRS score at 3 months after stroke onset by examining the patients. When physicians were unable to examine the patients, the mRS score was assessed by the attending physicians based on a review of the medical records or contacting the caregivers of patients.

Statistical Analysis

Categorical variables are presented as numbers and percentages, and continuous variables are presented as the means with standard deviations (SDs) or medians (interquartile ranges). The statistical significance of intergroup differences was evaluated using the χ^2 test for categorical variables and Student's *t* test, Mann–Whitney *U* test, or one-way analysis of variance for continuous variables as appropriate. The various baseline indicators listed in **Supplemental Table 1** were added to the following prediction models. Quantification theory type II was used as a multivariate linear discriminant model based on the assumption of a linear relationship between selected variables and the log odds of outcomes⁽²²⁾. This method is a discriminant analysis of qualitative data with external criteria of nominal scale, and both dependent variables and covariates are treated as categorical data. This method is equivalent to a linear discriminant analysis using dummy variables. The LLGMN analysis was used as a neural network analysis for a multivariate nonlinear discriminant model. This network analysis allows us to estimate the statistical distribution of sample data based on machine learning and predict the posterior probability of the class for unknown input data. A detailed description of the methods used for the LLGMN analysis is provided in the **Supplemental Materials**. From the results of those prediction models, we focused on the ALP levels at admission. Spearman's correlation analysis was conducted to determine the associations between ALP levels and other laboratory findings. Receiver operating characteristic (ROC) curves were constructed to obtain the optimal cutoff ALP levels to predict poor stroke outcome (mRS score of 3–6 at 3 months). Multivariable logistic analysis was conducted to identify predictors for the primary outcome by a backward selection procedure using *P* >

0.10 of the likelihood ratio test as the exclusion criterion. Those analyses were conducted using JMP 14.0 (SAS Institute, Inc., Cary, NC, USA).

Results

Baseline Characteristics and Laboratory Findings to Improve the Predictive Ability for Stroke Outcome

A total of 2,359 consecutive patients were enrolled. The flow chart of patient selection is shown in **Fig. 1A**. Among these patients, 443 patients were excluded due to premorbid mRS ≥ 3 . Of the remaining 1,956 patients, 737 patients were excluded due to lack of any abovementioned blood laboratory findings or lack of data on functional outcomes. Of the remaining 1,219 patients, 791 patients had good outcomes, and 428 patients had poor outcomes. Therefore, 800 patients were selected equally for good outcome (*n*=400) or poor outcome (*n*=400) by randomness extraction algorithms and analyzed using multivariate linear discriminant analysis (quantification theory type II) or LLGMN with 10-fold cross-validation. The area under the curve (AUC) of variables including age, sex, and the NIHSS score (reference) to predict poor outcome was 0.776 using multivariate linear discriminant analysis. The AUC of those variables was 0.819 using LLGMN. After adding the various indicators to age, sex, and the NIHSS score, each AUC value was evaluated. **Fig. 2** shows the indicators that ranked in the top 10 for improving the predictive ability. Both analyses revealed that several factors, such as ALP, CONUT score, albumin, and GNRI, were important factors for improving the predictive ability of AUC for poor stroke outcome.

The Associations between Alkaline Phosphatase and Baseline Characteristics

From the above results, we focused on the association between ALP values, baseline characteristics, and stroke outcomes. **Fig. 1B** shows the flow chart of patient selection. Finally, 1,484 patients were evaluated to analyze the associations between ALP, baseline characteristics, and stroke outcome. **Table 1** shows the baseline characteristics of the patients who were divided into four groups according to the quartiles of ALP values (≤ 192 , 193–238, 239–296, and ≥ 297 U/l). Increased ALP values were associated with older age and higher prevalence of previous stroke (*P*=0.016 and 0.025). Additionally, increased ALP values were associated with a higher GNRI and higher CAR (*P*=0.030 and <0.001). **Supplemental Table 2** shows Spearman's correlation

Table 1. Baseline characteristics by quartiles of ALP values

Factors	ALP Quartiles, U/l				<i>p</i>
	Q1 (≤ 192) (<i>n</i> = 374)	Q2 (193–238) (<i>n</i> = 371)	Q3 (239–296) (<i>n</i> = 368)	Q4 (≥ 297) (<i>n</i> = 371)	
Age, years	71.8 $\pm$ 12.8	73.0 $\pm$ 11.6	74.1 $\pm$ 10.8	74.1 $\pm$ 10.5	0.016
Sex, male	238 (63.6)	238 (64.2)	227 (61.7)	221 (59.6)	0.56
BMI, kg/m ² (<i>n</i> = 1,463)	23.4 $\pm$ 3.6	23.5 $\pm$ 3.9	23.2 $\pm$ 3.9	22.9 $\pm$ 3.8	0.19
Daily alcohol intake (<i>n</i> = 1,459)	113 (30.7)	118 (32.4)	112 (31.0)	91 (24.9)	0.11
Current smoking (<i>n</i> = 1,460)	67 (18.2)	89 (24.4)	84 (23.3)	73 (20.0)	0.14
Hypertension	266 (71.1)	242 (65.2)	267 (72.6)	254 (68.5)	0.14
Diabetes mellitus (<i>n</i> = 1,483)	134 (35.9)	136 (36.7)	113 (30.7)	131 (35.3)	0.32
Dyslipidaemia (<i>n</i> = 1,481)	196 (52.6)	179 (48.4)	193 (52.5)	166 (44.9)	0.11
Chronic kidney disease	150 (40.1)	156 (42.1)	147 (40.0)	136 (36.7)	0.51
Atrial fibrillation (<i>n</i> = 1,483)	87 (23.3)	72 (19.5)	80 (21.7)	76 (20.5)	0.62
Previous stroke (<i>n</i> = 1,483)	90 (24.1)	88 (23.7)	115 (31.3)	114 (30.7)	0.025
Previous ischaemic heart disease	56 (15.0)	49 (13.2)	48 (13.0)	51 (13.7)	0.87
NIHSS score at admission	3 (1–6)	3 (1–5)	3 (1–7.5)	3 (1–7)	0.46
Stroke subtype					0.31
Small-vessel occlusion	90 (24.1)	99 (26.7)	98 (26.6)	103 (27.8)	
Large-artery atherosclerosis	79 (21.1)	95 (25.6)	89 (24.2)	92 (24.8)	
Cardioembolic stroke	111 (29.7)	86 (23.2)	107 (29.1)	87 (23.5)	
Other aetiology	94 (25.1)	91 (24.5)	74 (20.1)	89 (24.0)	
Laboratory scores					
CONUT (<i>n</i> = 1,477)	1 (0.5–3)	1 (0–2)	1 (0–3)	2 (0–3)	0.07
GNRI (<i>n</i> = 1,454)	105.1 (98.4–111.9)	105.5 (98.4–111.5)	104.8 (97.8–111.1)	103.2 (94.4–110.6)	0.030
NLR (<i>n</i> = 1,479)	2.8 (1.8–4.7)	2.9 (2.0–4.1)	3.0 (1.9–5.3)	3.0 (2.0–5.0)	0.37
PLR (<i>n</i> = 1,479)	124.7 (95.3–171.2)	124.4 (98.4–166.0)	131.1 (97.8–184.4)	133.0 (92.4–184.4)	0.39
CAR (<i>n</i> = 1,470)	0.03 (0.02–0.09)	0.05 (0.02–0.10)	0.05 (0.02–0.13)	0.06 (0.02–0.23)	<0.001

Data are presented as the means $\pm$ standard deviation for age, BMI, and each laboratory finding; as median (interquartile range) for NIHSS score at admission, CONUT, GNRI, NLR, PLR, and CAR; and as number of patients (%) for others.

ALP, alkaline phosphatase; BMI, body mass index; NIHSS, National Institutes Health Stroke Scale. CONUT, Controlling Nutritional Status; GNRI, Geriatric Nutritional Risk Index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CAR, C reactive protein-to-albumin ratio

analysis between ALP values and other laboratory findings. Lower HDL, higher AST, higher ALT, higher LDH, higher γ -GTP, higher CRP, and higher D-dimer levels were closely associated with higher ALP levels ($P < 0.001$, respectively).

The Associations between Alkaline Phosphatase and Stroke Outcomes

Of 1,484 patients, 560 patients (37.7%) had poor outcomes (mRS score of 3–6) at 3 months after stroke onset. The patients with poor stroke outcomes were older and less likely to be male; had lower BMI, frequency of daily alcohol intake, and current smoking; had a higher frequency of CKD, atrial fibrillation, and previous stroke; and exhibited more severe NIHSS scores than those with good outcomes (Table 2). The patients with poor outcomes had higher ALP levels than those with good outcomes

(294.3 $\pm$ 259.5 vs. 246.3 $\pm$ 92.5 U/l, $P < 0.001$). Similarly, the patients with poor outcomes had higher CONUT, GNRI, NLR, PLR, and CAR than those with good outcomes ($P < 0.001$). Supplemental Table 3 shows other blood laboratory findings between the two groups. The optimal cutoff ALP level to predict patients with poor outcomes was ≥ 288 U/l, with a sensitivity of 55%, a specificity of 59%, and an area under the ROC curve of 0.578. Multivariable logistic analyses were conducted using the following three models. The variables included in model 1 were age, sex, BMI, daily alcohol intake, current smoking, comorbidities (hypertension, diabetes mellitus, dyslipidemia, CKD, and atrial fibrillation), previous stroke, previous ischemic heart disease, the NIHSS score, and ALP levels (quartiles range, 1-SD increase or optimal cutoff ALP level ≥ 288 U/l). For model 2, the other blood laboratory findings were added to

Fig. 1.

Flowchart of patient selection for (A) the prediction models for multivariate linear discriminant analysis (quantification theory type II) and neural network analysis (log-linearized Gaussian mixture network) and (B) the association between alkaline phosphatase (ALP) levels, baseline characteristics, and stroke outcome.

Fig. 2. The area under the curve (AUC) from the receiver operating characteristic curve was used to predict stroke outcome of the 10 highest ranked variables

(A) Multivariate linear discriminant analysis, (B) log-linearized Gaussian mixture network analysis. References indicated age, sex, and National Institutes of Health Stroke Scale score.

ALP, alkaline phosphatase; CONUT, Controlling Nutritional Status; Alb, albumin, GNRI, Geriatric Nutritional Risk Index; LDH, lactate dehydrogenase, NLR, neutrophil-to-lymphocyte ratio; CRP, C-reactive protein; PLR, platelet-to-lymphocyte ratio; ChE, cholinesterase.

Table 2. Baseline characteristics associated with 3-month functional outcome

	mRS 0-2 (<i>n</i> = 960)	mRS 3-6 (<i>n</i> = 524)	<i>p</i>
Age, years	70.8 ± 11.5	77.8 ± 9.9	<0.001
Sex, male	640 (66.7)	284 (54.2)	<0.001
BMI, kg/m ² (<i>n</i> = 1,463)	23.6 ± 3.7	22.6 ± 3.8	<0.001
Daily alcohol intake (<i>n</i> = 1,459)	310 (32.7)	124 (24.3)	<0.001
Current smoking (<i>n</i> = 1,460)	240 (25.3)	73 (14.3)	<0.001
Hypertension	658 (68.5)	371 (70.8)	0.38
Diabetes mellitus (<i>n</i> = 1,483)	336 (35.0)	178 (34.0)	0.73
Dyslipidaemia (<i>n</i> = 1,481)	493 (51.4)	241 (46.3)	0.06
Chronic kidney disease	340 (35.4)	249 (47.5)	<0.001
Atrial fibrillation (<i>n</i> = 1,483)	156 (16.3)	159 (30.4)	<0.001
Previous stroke (<i>n</i> = 1,483)	238 (24.8)	169 (32.3)	0.002
Previous ischaemic heart disease	120 (12.5)	84 (16.0)	0.06
NIHSS score at admission	2 (1–4)	7 (3–17)	<0.001
Stroke subtype			<0.001
Small-vessel occlusion	281 (29.3)	109 (20.8)	
Large-artery atherosclerosis	242 (25.2)	113 (21.6)	
Cardioembolic stroke	211 (22.0)	180 (34.4)	
Other aetiology	226 (23.5)	122 (23.3)	
Laboratory findings	71 (29.3)	49 (35.0)	
ALP levels U/l	246.3 ± 92.5	294.3 ± 259.5	<0.001
CONUT (<i>n</i> = 1,477)	1 (0–2)	2 (1–3)	<0.001
GNRI (<i>n</i> = 1,454)	106.3 (100.1–112.8)	100.4 (92.8–107.6)	<0.001
NLR (<i>n</i> = 1,479)	2.6 (1.8–3.9)	3.9 (2.3–6.6)	<0.001
PLR (<i>n</i> = 1,479)	122.8 (93.8–168.4)	142.6 (100.0–204.7)	<0.001
CAR (<i>n</i> = 1,470)	0.04 (0.02–0.09)	0.07 (0.03–0.34)	<0.001

Data are presented as the means ± standard deviation for age, BMI, and each laboratory finding; as median (interquartile range) for NIHSS score at admission, CONUT, GNRI, NLR, PLR, and CAR; and as number of patients (%) for others. ALP, alkaline phosphatase; BMI, body mass index; NIHSS, National Institutes Health Stroke scale. CONUT, Controlling Nutritional Status; GNRI, Geriatric Nutritional Risk Index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CAR, C reactive protein-to-albumin ratio

model 1. For model 3, scores calculated from blood laboratory findings (CONUT scores, GNRI, NLR, PLR, and CAR) were added to model 1. Multivariable analysis revealed that increased ALP levels were independently associated with poor stroke outcome after adjusting for several baseline characteristics and laboratory findings (Table 3). For other candidate parameters (albumin, CONUT score, and GNRI) extracted from prediction models, ALP levels as a 1-SD increase were adopted as follows. Serum albumin levels were independently associated with poor stroke outcome (odds ratio (OR) 0.46, 95% confidence interval (CI) 0.34–0.61, $P < 0.001$, model 2). Higher CONUT score and lower GNRI were also associated with poor stroke outcome (OR 1.15, 95% CI 1.04–1.26, $P = 0.006$ and OR 0.98, 95% CI 0.96–0.99, $P = 0.008$, respectively, model 3).

Of 1,484 patients, 83 patients (5.6%) had died at 3 months after stroke onset. The patients who had died by 3 months had higher ALP levels than survivors

(412.6 ± 565.2 vs. 254.4 ± 107.0 U/l, $P < 0.001$). Multivariable analysis revealed that a 1-SD increase in ALP levels was independently associated with mortality (OR 1.42, 95% CI 1.18–1.70, $P < 0.001$, model 1, and OR 1.40, 95% CI 1.11–1.76, $P < 0.001$, model 3) although these associations were not significant according to the analysis of model 2 (OR 1.30, 95% CI 0.98–1.73, $P = 0.067$).

For the analysis of secondary outcome on mRS scores of 0–1 at 3 months, 194 patients with a pre-morbid mRS score of 2 were excluded. Of the remaining 1,290 patients, 699 patients had mRS scores of 0–1 at 3 months (54.2%). The patients with mRS scores of 2–6 had higher ALP levels than those with mRS scores of 0–1 (278.1 ± 214.5 vs. 245.7 ± 93.7 U/l, $P = 0.001$). Multivariable analysis revealed that a 1-SD increase in ALP levels was independently associated with mRS scores of 2–6 at 3 months (OR 1.21 95% CI 1.02–1.45, $P = 0.015$, model 1, and OR 1.26, 95% CI 1.03–1.54, $P = 0.014$, model 3),

Table 3. Odds ratio (95% CI) for poor functional outcome at 3 months by quartiles, 1-SD change and optimal cut-off value in alkaline phosphatase levels

	ALP Quartiles, U/L				1-SD increase in ALP levels	ALP (≥ 288) vs. ALP (< 288)
	Q1 (≤ 192) ($n = 374$)	Q2 (193–238) ($n = 371$)	Q3 (239–296) ($n = 368$)	Q4 (≥ 297) ($n = 371$)		
Model 1	1.00	1.04 (0.70–1.55)	1.64 (1.12–2.41)	1.98 (1.36–2.90)	1.30 (1.11–1.56)	1.88 (1.42–2.48)
Model 2	1.00	1.01 (0.66–1.52)	1.62 (1.10–2.42)	1.80 (1.21–2.68)	1.21 (1.02–1.49)	1.81 (1.35–2.42)
Model 3	1.00	1.06 (0.70–1.60)	1.72 (1.16–2.54)	1.91 (1.29–2.83)	1.31 (1.09–1.61)	1.76 (1.32–2.33)

Model 1: age, sex, body mass index, daily alcohol intake, current smoking, comorbidities (hypertension, diabetes mellitus, dyslipidaemia, chronic kidney disease and atrial fibrillation), previous stroke, previous ischaemic heart disease, National Institutes Health Stroke Scale, ALP levels (quartiles range or 1-SD increase).

Model 2; the other blood laboratory findings were added to model 1.

Model 3: Calculated scores (CONUT, GNRI, NLR, PLR, and CAR) were added to model 1.

ALP, alkaline phosphatase; CONUT, Controlling Nutritional Status; GNRI, Geriatric Nutritional Risk Index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CAR, C reactive protein-to-albumin ratio

although those associations were not significant according to the analysis of model 2. Conversely, a 1-SD increase in ALP levels was independently associated with mRS scores of 3–6 at 3 months among patients with a premorbid mRS score of 0–1 in each model (OR 1.32 95% CI 1.10–1.59, $P < 0.001$, model 1, OR 1.24, 95% CI 1.01–1.53, $P = 0.041$, model 2 and OR 1.34, 95% CI 1.09–1.66, $P = 0.002$, model 3).

Discussion

In the present study, by using multivariate linear discriminant or neural network analysis, ALP has been found to be a promising biological marker for improving the predictive ability for stroke outcomes when added to age, sex, and the NIHSS score. Additionally, after adjusting for baseline characteristics and other blood parameters, increased ALP levels were independently associated with poor stroke outcome.

A neural network analysis, a kind of machine learning, is an algorithm that works with a large number or possible predictor variables. Recently, this method has been applied in the medical field because it can predict disease severity or classification. In the present study, by using traditional or neural network analysis, ALP and nutritional status (CONUT score, albumin, or GNRI) have been found to be promising biological markers to predict functional stroke outcome. Remarkably, almost all AUC values used to predict poor outcomes with LLGMN were relatively higher than the AUC values obtained using a traditional analysis. Thus, the machine learning method may be superior to the traditional method. The CONUT score, an index calculated from the serum albumin concentration, total peripheral lymphocyte count, and total cholesterol concentration,

is a screening tool for nutritional evaluation that has been validated in hospital populations⁵). We reported previously that malnutritional status using the CONUT score was independently associated with poor stroke outcomes among acute ischemic stroke ($n = 230$)⁴. Compared with that in our previous study, in the present study, the CONUT score has been confirmed to be a useful indicator for predicting stroke outcome in a large cohort. Only albumin might be a useful marker for predicting stroke outcome from our prediction models, although albumin is a component factor of the CONUT score. Indeed, several clinical studies have reported that reduced serum albumin levels in acute stroke patients were associated with poor outcomes^{23, 24}. The GNRI, which was calculated from serum albumin levels and BMI, was also associated with poor stroke outcomes²⁵. In any case, assessments of nutritional status at admission are essential among acute ischemic stroke patients because malnourished stroke patients have a higher frequency of pneumonia, other infections, gastrointestinal bleeding, and bedsores than nourished patients²⁶. Our findings provided further evidence that several nutritional indicators selected from prediction models were important factors for predicting stroke outcome.

Interestingly, besides nutritional status, serum ALP levels were ranked highly for improving the predictive ability for stroke outcome from both multivariate linear discriminant and neural network analyses. Therefore, we focused on the association between ALP levels, baseline characteristics, and stroke outcome in the present study. Serum ALP is usually used as a marker of liver disease or biliary obstructive disease in clinical settings. Recently, several studies have found that increased ALP levels were associated with cardiovascular events or mortality in the general

population²⁷⁻²⁹). Kunutsor *et al.* reported that the multivariate relative risk for cardiovascular events per 1-SD change in baseline ALP was 1.09 (95% CI 1.02–1.16) in a meta-analysis³⁰. Additionally, studies regarding ALP as a prognostic stroke biological marker³¹⁻³³ had been accumulated. In the present study, we found that increased ALP levels at admission were independently associated with poor outcome at 3 months post-stroke onset after adjustments for other important parameters, including nutritional status related to stroke outcome.

Several possible mechanisms for the association between increased ALP levels and poor outcomes after stroke have been proposed. First, increased ALP levels have been implicated in the pathogenesis of vascular calcification³⁴. Vascular calcification is known to cause cardiovascular morbidity and mortality, and aortic calcification increases the relative risk of stroke^{35, 36}. Second, serum ALP levels are also associated with inflammation or malnutrition^{33, 37}. Indeed, in the present study, increased ALP levels were associated with CRP levels, D-dimer levels, and several nutritional statuses. However, we found that increased ALP levels were independently associated with poor stroke outcome after adjustment for those indicators. Hence, the association between ALP and poor stroke outcome is less likely to be merely dependent on malnutritional status and inflammation. Third, several basic studies have shown that ALP activity can be expressed in brain endothelial cells and neurons^{38, 39}. Lee *et al.* found that increased ALP levels were associated with the presence of cerebral small vessel disease⁴⁰. These basic and clinical findings might indicate that ALP plays a role in the blood–brain barrier (BBB) breakdown, neuroinflammation, and vascular dysfunction in stroke patients⁴¹. The mechanisms underlying the associations between increased ALP levels, neuroinflammation, BBB permeability, and vascular homeostasis might contribute to poor stroke outcomes⁴¹.

Our study has several limitations. First, we excluded patients with intravenous thrombolysis or endovascular therapy because those therapies are strongly associated with stroke outcome. Additionally, not all subjects could be evaluated for blood laboratory parameters, which might lead to potential selection bias. Second, the AUC of ALP levels alone as a predictor of poor outcomes was not very high. Additionally, a 1-SD increase in ALP levels was not independently associated with secondary outcomes (mRS score of 2–6 at 3 months or mortality) after adjusting for other laboratory findings from blood samples (model 2). A larger validation cohort may be required to verify the usefulness of ALP levels as a

predictor of various stroke outcomes. Third, we could not evaluate serum phosphate levels or 25-hydroxyvitamin D levels. We were also unable to evaluate bone disease affecting serum ALP levels. Interactions between ALP, phosphate, and vitamin D levels are associated with calcium and bone metabolism. Fourth, we did not evaluate detailed information on liver diseases that affect serum ALP levels. However, we could evaluate the daily alcohol intake and other liver enzymes. Multivariable analysis was conducted and adjusted for those influences. Serum ALP included several isoenzymes derived from the bone, liver, intestine, and so on. Further studies may be needed to elucidate the mechanism of association between increased specific ALP levels and poor stroke outcome.

To conclude, we determined prognostic factors such as ALP levels and nutritional status from prediction models of the multivariate linear discriminant and neural network analyses among acute ischemic stroke patients. These indicators were independently associated with functional outcome. Nutritional management is necessary for improving stroke outcome, and accurate nutritional intervention may prevent weight loss and enhance the muscle strength and quality of life of malnourished patients with stroke⁴². Recently, a novel treatment that lowers ALP levels has been proposed to reduce the risk of cardiovascular events⁴³. Active nutritional intervention and ALP-targeted treatments will be expected for acute ischemic stroke patients.

Sources of Funding

This study was supported by research grant from the Japan Society for the Promotion of Science KAKENHI (Grant Numbers 20K16579).

Disclosures

Hirofumi Maruyama received grants from the Daiichi Sankyo Co., Ltd.; these grants are unrelated to the submitted work.

All other authors declare that they have no conflicts of interest.

References

- 1) Weimar C, König IR, Kraywinkel K, Ziegler A, Diener HC, Collaboration GSS. Age and national institutes of health stroke scale score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: Development and external validation of prognostic models. *Stroke*, 2004; 35: 158-162
- 2) König IR, Ziegler A, Bluhmki E, Hacke W, Bath PM,

- Sacco RL, et al. Predicting long-term outcome after acute ischemic stroke: A simple index works in patients from controlled clinical trials. *Stroke*, 2008; 39: 1821-1826
- 3) Collaboration GSS. Predicting outcome after acute ischemic stroke: An external validation of prognostic models. *Neurology*, 2004; 62: 581-585
 - 4) Naito H, Nezu T, Hosomi N, Aoki S, Kinoshita N, Kuga J, et al. Controlling nutritional status score for predicting 3-mo functional outcome in acute ischemic stroke. *Nutrition*, 2018; 55-56: 1-6
 - 5) Ignacio de Ulíbarri J, González-Madroño A, de Villar NG, González P, González B, Mancha A, et al. Conut: A tool for controlling nutritional status. First validation in a hospital population. *Nutr Hosp*, 2005; 20: 38-45
 - 6) Zhang Y, Jiang L, Yang P. Comparison of lymphocyte count, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in predicting the severity and the clinical outcomes of acute cerebral infarction patients. *Clin Lab*, 2019; 65
 - 7) Wang L, Song Q, Wang C, Wu S, Deng L, Li Y, et al. Neutrophil to lymphocyte ratio predicts poor outcomes after acute ischemic stroke: A cohort study and systematic review. *J Neurol Sci*, 2019; 406: 116445
 - 8) Altintas O, Altintas MO, Tasal A, Kucukdagli OT, Asil T. The relationship of platelet-to-lymphocyte ratio with clinical outcome and final infarct core in acute ischemic stroke patients who have undergone endovascular therapy. *Neurol Res*, 2016; 38: 759-765
 - 9) Mazaheri S, Reisi E, Poorolajal J, Ghiasian M. C-reactive protein levels and clinical outcomes in stroke patients: A prospective cohort study. *Arch Iran Med*, 2018; 21: 8-12
 - 10) Matsuo R, Ago T, Hata J, Wakisaka Y, Kuroda J, Kuwashiro T, et al. Plasma c-reactive protein and clinical outcomes after acute ischemic stroke: A prospective observational study. *PLoS One*, 2016; 11: e0156790
 - 11) Kubo S, Hosomi N, Hara N, Neshige S, Himeno T, Takeshima S, et al. Ischemic stroke mortality is more strongly associated with anemia on admission than with underweight status. *J Stroke Cerebrovasc Dis*, 2017; 26: 1369-1374
 - 12) Yang XY, Gao S, Ding J, Chen Y, Zhou XS, Wang JE. Plasma d-dimer predicts short-term poor outcome after acute ischemic stroke. *PLoS One*, 2014; 9: e89756
 - 13) Nezu T, Kitano T, Kubo S, Uemura J, Yamashita S, Iwanaga T, et al. Impact of d-dimer levels for short-term or long-term outcomes in cryptogenic stroke patients. *J Neurol*, 2018; 265: 628-636
 - 14) Widhi Nugroho A, Arima H, Miyazawa I, Fujii T, Miyamatsu N, Sugimoto Y, et al. The association between glomerular filtration rate estimated on admission and acute stroke outcome: The shiga stroke registry. *J Atheroscler Thromb*, 2018; 25: 570-579
 - 15) Shima K, Tsuji T, Kandori A, Yokoe M, Sakoda S. Measurement and evaluation of finger tapping movements using log-linearized gaussian mixture networks. *Sensors (Basel)*, 2009; 9: 2187-2201
 - 16) Tsuji T, Bu N, Fukuda O, Kaneko M. A recurrent log-linearized gaussian mixture network. *IEEE Trans Neural Netw*, 2003; 14: 304-316
 - 17) Ichinose N, Hama S, Tsuji T, Soh Z, Hayashi H, Kiura Y, et al. Predicting ischemic stroke after carotid artery stenting based on proximal calcification and the jellyfish sign. *J Neurosurg*, 2018; 128: 1280-1288
 - 18) Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated gfr from serum creatinine in japan. *Am J Kidney Dis*, 2009; 53: 982-992
 - 19) Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. *Stroke*, 1993; 24: 35-41
 - 20) Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric nutritional risk index: A new index for evaluating at-risk elderly medical patients. *Am J Clin Nutr*, 2005; 82: 777-783
 - 21) Xu XL, Yu HQ, Hu W, Song Q, Mao WM. A novel inflammation-based prognostic score, the c-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. *PLoS One*, 2015; 10: e0138657
 - 22) Suzuki T, Kudo A. Recent application of quantification ii in japanese medical research. *Environ Health Perspect*, 1979; 32: 131-141
 - 23) Dziedzic T, Slowik A, Szczudlik A. Serum albumin level as a predictor of ischemic stroke outcome. *Stroke*, 2004; 35: e156-158
 - 24) Babu MS, Kaul S, Dadheech S, Rajeshwar K, Jyothy A, Munshi A. Serum albumin levels in ischemic stroke and its subtypes: Correlation with clinical outcome. *Nutrition*, 2013; 29: 872-875
 - 25) Kang MK, Kim TJ, Kim Y, Nam KW, Jeong HY, Kim SK, et al. Geriatric nutritional risk index predicts poor outcomes in patients with acute ischemic stroke - automated undernutrition screen tool. *PLoS One*, 2020; 15: e0228738
 - 26) Collaboration FT. Poor nutritional status on admission predicts poor outcomes after stroke: Observational data from the food trial. *Stroke*, 2003; 34: 1450-1456
 - 27) Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Gregson J, Dullaart RP. Serum alkaline phosphatase and risk of incident cardiovascular disease: Interrelationship with high sensitivity c-reactive protein. *PLoS One*, 2015; 10: e0132822
 - 28) Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML, et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. *Circulation*, 2009; 120: 1784-1792
 - 29) Abramowitz M, Muntner P, Coco M, Southern W, Lotwin I, Hostetter TH, et al. Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. *Clin J Am Soc Nephrol*, 2010; 5: 1064-1071
 - 30) Kunutsor SK, Apekey TA, Khan H. Liver enzymes and risk of cardiovascular disease in the general population: A meta-analysis of prospective cohort studies. *Atherosclerosis*, 2014; 236: 7-17
 - 31) Kim J, Song TJ, Song D, Lee HS, Nam CM, Nam HS, et al. Serum alkaline phosphatase and phosphate in cerebral atherosclerosis and functional outcomes after cerebral infarction. *Stroke*, 2013; 44: 3547-3549
 - 32) Zong L, Wang X, Li Z, Zhao X, Liu L, Li H, et al. Alkaline phosphatase and outcomes in patients with preserved renal function: Results from china national stroke registry.

- Stroke, 2018; 49: 1176-1182
- 33) Ryu WS, Lee SH, Kim CK, Kim BJ, Yoon BW. Increased serum alkaline phosphatase as a predictor of long-term mortality after stroke. *Neurology*, 2010; 75: 1995-2002
 - 34) Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: Pathobiological mechanisms and clinical implications. *Circ Res*, 2006; 99: 1044-1059
 - 35) Adler Y, Fink N, Spector D, Wiser I, Sagie A. Mitral annulus calcification--a window to diffuse atherosclerosis of the vascular system. *Atherosclerosis*, 2001; 155: 1-8
 - 36) Hollander M, Hak AE, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, et al. Comparison between measures of atherosclerosis and risk of stroke: The rotterdam study. *Stroke*, 2003; 34: 2367-2372
 - 37) Wannamethee SG, Sattar N, Papcosta O, Lennon L, Whincup PH. Alkaline phosphatase, serum phosphate, and incident cardiovascular disease and total mortality in older men. *Arterioscler Thromb Vasc Biol*, 2013; 33: 1070-1076
 - 38) Ermonval M, Baudry A, Baychelier F, Pradines E, Pietri M, Oda K, et al. The cellular prion protein interacts with the tissue non-specific alkaline phosphatase in membrane microdomains of bioaminergic neuronal cells. *PLoS One*, 2009; 4: e6497
 - 39) Brun-Heath I, Ermonval M, Chabrol E, Xiao J, Palkovits M, Lyck R, et al. Differential expression of the bone and the liver tissue non-specific alkaline phosphatase isoforms in brain tissues. *Cell Tissue Res*, 2011; 343: 521-536
 - 40) Lee HB, Kim J, Kim SH, Kim S, Kim OJ, Oh SH. Association between serum alkaline phosphatase level and cerebral small vessel disease. *PLoS One*, 2015; 10: e0143355
 - 41) Brichacek AL, Brown CM. Alkaline phosphatase: A potential biomarker for stroke and implications for treatment. *Metab Brain Dis*, 2019; 34: 3-19
 - 42) Ha L, Hauge T, Spenning AB, Iversen PO. Individual, nutritional support prevents undernutrition, increases muscle strength and improves qol among elderly at nutritional risk hospitalized for acute stroke: A randomized, controlled trial. *Clin Nutr*, 2010; 29: 567-573
 - 43) Filippakopoulos P, Knapp S. The bromodomain interaction module. *FEBS Lett*, 2012; 586: 2692-2704

SUPPLEMENTAL MATERIAL

The Methods of Log-Linearized Gaussian Mixture Network (LLGMN)

The input to LLGMN is a P -dimensional evaluation index, $\mathbf{z}^{(n)} = [z_1^{(n)}, z_2^{(n)}, \dots, z_P^{(n)}]^T \in \mathbb{R}^P$, obtained from various indicators, where n identifies the patient. The output is a two-dimensional posterior probability vector, $\mathbf{Y}^{(n)} \in \mathbb{R}^2$, representing either good or poor functional outcome. The training dataset comprised evaluation indices $\mathbf{z}^{(n)}$ ($n=1, 2, \dots, N$) from N patients out of the $M=800$ patients as training inputs and corresponding labels (good or poor outcomes) $\mathbf{Q}^{(n)} \in \mathbb{R}^2$. After training the models, the prediction accuracy was verified by the validation

dataset composed of the data excluded from the training dataset. Posterior probabilities $\mathbf{Y}^{(n')}$ ($n'=1, 2, \dots, N'$; N' is the number of patients in the validation dataset) of the primary outcome were predicted by inputting validation inputs $\mathbf{z}^{(n')}$ to the models. The prediction accuracy of the functional outcome was then evaluated using the area under the curve (AUC) from the receiver operating characteristic curve on predicted posterior probability $\mathbf{Y}^{(n')}$ and true label $\mathbf{Q}^{(n')}$. Training and validation of the models for calculating the AUC were conducted based on the 10-fold cross-validation. Baseline AUCs (reference) were calculated from the following indicators: age, sex, and the National Institutes of Health Stroke Scale score in both prediction models.

Supplement Table 1. Indicators added to the prediction models

Categorical variables	Laboratory findings (continuous variables)
Daily alcohol intake	Haemoglobin (g/dl)
Current smoking	White blood cell (/μl)
Hypertension	Lymphocyte count (/μl)
Diabetes mellitus	Neutrophil count (/μl)
Dyslipidaemia	Platelets ($\times 10^4$ /μl)
Atrial fibrillation	Albumin (g/dl)
Previous stroke	Total cholesterol (mg/dl)
Previous ischaemic heart disease	LDL cholesterol (mg/dl)
Calculated scores (continuous variables)	HDL cholesterol (mg/dl)
BMI (kg/m ²)	TG (mg/dl)
eGFR (L/min/1.73 m ²)	Cholinesterase (U/I)
CONUT score	AST (U/I)
GNRI	ALT (U/I)
NLR	LDH (U/I)
PLR	γ-GTP (U/I)
CAR	BUN (mg/dl)
	Cr (mg/dl)
	HbA1c (%)
	CRP (mg/dl)
	D-dimer (μg/mL)

BMI, body mass index; eGFR, estimated glomerular filtration rate; CONUT, Controlling Nutritional Status; GNRI, Geriatric Nutritional Risk Index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CAR, C reactive protein-to-albumin ratio; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; γ-GTP, γ-glutamyl transpeptidase; BUN, blood urea nitrogen; Cr, creatinine; HbA1c, haemoglobin A1c; CRP, C-reactive protein.

Supplement Table 2. Correlation of alkaline phosphatase to laboratory findings

Laboratory findings	ALP (<i>n</i> = 1,484)	
	ρ	<i>P</i>
Haemoglobin (g/dl)	0.025	0.34
White blood cell (/ μ l) (<i>n</i> = 1,483)	0.041	0.11
Lymphocyte count (/ μ l) (<i>n</i> = 1,481)	-0.024	0.35
Neutrophil count (/ μ l) (<i>n</i> = 1,481)	0.051	0.049
Platelet ($\times 10^4$ / μ l) (<i>n</i> = 1,482)	0.053	0.042
Albumin (g/dl) (<i>n</i> = 1,475)	-0.065	0.012
Total cholesterol (mg/dl) (<i>n</i> = 1,474)	-0.028	0.28
LDL cholesterol (mg/dl) (<i>n</i> = 1,455)	0.006	0.83
HDL cholesterol (mg/dl) (<i>n</i> = 1,453)	-0.098	<0.001
TG (mg/dl) (<i>n</i> = 1,466)	0.020	0.45
Cholinesterase (U/I) (<i>n</i> = 1,424)	-0.041	0.12
AST (U/I)	0.103	<0.001
ALT (U/I)	0.078	<0.001
LDH (U/I) (<i>n</i> = 1,478)	0.104	<0.001
γ -GTP (U/I) (<i>n</i> = 1,472)	0.137	<0.001
BUN (mg/dl)	-0.018	0.50
Cr (mg/dl)	-0.074	0.005
eGFR (L/min/1.73 m ²)	0.041	0.12
HbA1c (%) (<i>n</i> = 1,450)	0.002	0.94
CRP (mg/dl) (<i>n</i> = 1,477)	0.161	<0.001
D-dimer (μ g/mL) (<i>n</i> = 1,435)	0.106	<0.001

LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; γ -GTP, γ -glutamyl transpeptidase; BUN, blood urea nitrogen; Cr, creatinine; HbA1c, haemoglobin A1c; CRP, C-reactive protein.

Supplement Table 3. Laboratory findings associated with 3-month functional outcome

	mRS 0-2 (<i>n</i> = 960)	mRS 3-6 (<i>n</i> = 524)	<i>p</i>
Haemoglobin (g/dl)	13.7 $\pm$ 2.1	13.0 $\pm$ 2.3	<0.001
White blood cell (/ μ l) (<i>n</i> = 1,483)	7016.7 $\pm$ 2686.2	7943.8 $\pm$ 3641.0	<0.001
Lymphocyte count (/ μ l) (<i>n</i> = 1,481)	1720.8 $\pm$ 823.8	1415.9 $\pm$ 719.5	<0.001
Neutrophil count (/ μ l) (<i>n</i> = 1,481)	4692.5 $\pm$ 2277.4	5981.8 $\pm$ 3525.6	<0.001
Platelet ($\times 10^4$ / μ l) (<i>n</i> = 1,482)	20.8 $\pm$ 7.6	19.3 $\pm$ 9.4	0.001
Albumin (g/dl) (<i>n</i> = 1,475)	4.1 $\pm$ 0.5	3.8 $\pm$ 0.6	<0.001
Total cholesterol (mg/dl) (<i>n</i> = 1,474)	194.5 $\pm$ 42.9	188.9 $\pm$ 47.3	0.020
LDL cholesterol (mg/dl) (<i>n</i> = 1,455)	116.3 $\pm$ 36.9	114.6 $\pm$ 38.3	0.41
HDL cholesterol (mg/dl) (<i>n</i> = 1,453)	52.0 $\pm$ 15.4	51.0 $\pm$ 14.6	0.22
TG (mg/dl) (<i>n</i> = 1,466)	130.8 $\pm$ 92.7	108.4 $\pm$ 77.3	<0.001
Cholinesterase (U/I) (<i>n</i> = 1,424)	296.2 $\pm$ 79.6	260.4 $\pm$ 86.7	0.002
AST (U/I)	25.1 $\pm$ 12.9	31.3 $\pm$ 28.0	<0.001
ALT (U/I)	22.3 $\pm$ 17.6	24.2 $\pm$ 55.5	0.34
LDH (U/I) (<i>n</i> = 1,478)	210.9 $\pm$ 57.2	261.8 $\pm$ 134.2	<0.001
γ -GTP (U/I) (<i>n</i> = 1,472)	43.7 $\pm$ 58.3	45.8 $\pm$ 84.9	0.57
BUN (mg/dl)	17.9 $\pm$ 10.2	20.8 $\pm$ 12.8	<0.001
Cr (mg/dl)	1.14 $\pm$ 1.61	1.07 $\pm$ 1.12	0.41
eGFR (L/min/1.73 m ²)	67.0 $\pm$ 24.6	63.2 $\pm$ 27.5	0.007
HbA1c (%) (<i>n</i> = 1,450)	6.1 $\pm$ 1.2	6.1 $\pm$ 1.1	0.65
CRP (mg/dl) (<i>n</i> = 1,477)	0.17 (0.1–0.4)	0.3 (0.1–1.2)	<0.001
D-dimer (μ g/mL) (<i>n</i> = 1,435)	0.9 (0.6–1.4)	1.7 (0.9–3.8)	<0.001